|
admission versus control group
|
Natural killer cell mediated cytotoxicity
|
3.142005e−09
|
|
Graft-versus-host disease
|
5.779472e−07
|
|
Antigen processing and presentation
|
2.997803e−03
|
|
Cytosolic DNA-sensing pathway
|
2.302012e−02
|
|
discharge versus control group
|
Natural killer cell mediated cytotoxicity
|
8.154634e−10
|
|
Graft-versus-host disease
|
1.164728e−08
|
|
Antigen processing and presentation
|
1.657503e−04
|
|
Allograft rejection
|
2.438676e−02
|
|
admission versus 6 months
|
Oxidative phosphorylation
|
3.841450e−15
|
|
Huntington’s disease
|
1.570003e−12
|
|
Parkinson’s disease
|
2.462576e−12
|
|
Alzheimer’s disease
|
1.076534e−11
|
|
discharge versus 6 months
|
Parkinson’s disease
|
4.627948e−16
|
|
Oxidative phosphorylation
|
4.627948e−16
|
|
Alzheimer’s disease
|
9.071314e−15
|
|
Huntington’s disease
|
8.428429e−14
|
